Johnson & Johnson, the global healthcare company, has announced the pricing of its multi-tranche notes offering on May 14, 2024. The offering includes 3.200% notes due 2032, 3.350% notes due 2036, and 3.550% notes due 2044, with a total size of €2.5 billion. The notes are expected to settle on May 20, 2024, and will be listed on the New York Stock Exchange. The proceeds from the offering are anticipated to be used for general corporate purposes. The notes have been rated Aaa (stable) by Moody's and AAA (negative) by S&P. The joint book-running managers for the offering include J.P. Morgan Securities, Citigroup Global Markets, and several other notable financial institutions. The offering is targeted at eligible counterparties and professional clients only, with sales to EEA/UK retail investors being prohibited.

Johnson & Johnson, the global healthcare company, has announced the pricing of its multi-tranche notes offering on May 14, 2024. The offering includes 3.200% notes due 2032, 3.350% notes due 2036, and 3.550% notes due 2044, with a total size of €2.5 billion. The notes are expected to settle on May 20, 2024, and will be listed on the New York Stock Exchange. The proceeds from the offering are anticipated to be used for general corporate purposes. The notes have been rated Aaa (stable) by Moody's and AAA (negative) by S&P. The joint book-running managers for the offering include J.P. Morgan Securities, Citigroup Global Markets, and several other notable financial institutions. The offering is targeted at eligible counterparties and professional clients only, with sales to EEA/UK retail investors being prohibited.